Roche

News

Roche's Gazyva shows promise in Lupus nephritis trial

Roche’s Gazyva is already approved in leukaemia and lymphoma – but could it work in the autoimmune kidney disease Lupus nephritis too?

News

FDA approves Roche's $90,000 lymphoma combination

The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – costing in the region of $90,000 for a four-month course.

News

Roche delays Spark merger again amid reviews in US and UK

Roche’s $4.3 billion takeover of US gene therapy specialist Spark Therapeutics has been pushed back again because regulators are concerned over its impact on competition.

News

Sanofi names ex-Roche cancer guru Dietmar Berger as developm...

Roche alumnus Dietmar Berger has joined Sanofi as head of development following a short stint in biotech.

News

Merck & Co's Keytruda fails in triple negative breast cancer...

Most of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of cancers – but it has produced an uncharacteristic failure in tough to treat tri

News

Campaigners urge NHS to drop Roche acne drug

Campaigners are demanding that the NHS stop prescribing Roche’s acne drug Roaccutane (isotretinoin), claiming it can lead to erectile dysfunction and suicide.

Roche's Gazyva shows promise in Lupus nephritis trial

FDA approves Roche's $90,000 lymphoma combination

Roche delays Spark merger again amid reviews in US and UK

Sanofi names ex-Roche cancer guru Dietmar Berger as developm...

Merck & Co's Keytruda fails in triple negative breast cancer...

Campaigners urge NHS to drop Roche acne drug

AI specialists Enveda and Basecamp rake in the cash

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks